Upgrade to SI Premium - Free Trial

AbbVie (ABBV) Reports New Data from Phase 3 MURANO Trial of VENCLEXTA/VENCLYXTO (venetoclax) in Combination with Rituximab

December 3, 2018 6:10 AM
AbbVie (NYSE: ABBV) presented updated data from the pivotal Phase 3 MURANO trial of venetoclax (VENCLEXTA® or VENCLYXTO®) in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles